Corellia AI

Executive Summary

Corellia AI is a private biotechnology company spun out from Champions Oncology in 2023, headquartered in San Francisco. The company leverages AI-enabled workflows to accelerate the discovery and development of first-in-class oncology therapeutics. Its core competitive advantage lies in a proprietary research ecosystem built on a deep multi-omic cancer dataset and one of the largest banks of predictive tumor models. By integrating these assets with machine learning, Corellia aims to identify novel drug targets and optimize candidate molecules with higher speed and efficiency than traditional approaches, addressing significant unmet needs in oncology. Though still in early stages, Corellia AI's approach has the potential to streamline the historically expensive and failure-prone drug development process. The company's spin-out from Champions Oncology provides access to validated biological tools and clinical insights, reducing technical risk. With a focus on first-in-class therapies, Corellia targets high-reward opportunities but faces typical biotech challenges including capital needs and regulatory hurdles. Its near-term value hinges on advancing its pipeline toward clinical validation and securing additional funding or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Announcement of lead program nomination70% success
• Q1 2027Series A funding round close60% success
• Q2 2027Collaboration or licensing deal with major pharma40% success